Ritter Pharmaceuticals (NASDAQ:RTTR) has engaged Alliance Global Partners as a financial advisor to help the company evaluate strategic alternatives.
The company is considering a variety of options, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions.
On Sept. 12, the company reported that its Phase 3 clinical trial of RP-G28 for the treatment of lactose intolerance failed to demonstrate statistically significant symptom improvements compared to placebo.
